Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent~2. Women aged ≥ 18 years~3. Histologically confirmed invasive breast cancer~4. American Joint Committee on Cancer (AJCC) stage: ⅡA-ⅢC, no evidence of metastasis~5. At least one measurable disease in breast and/or axilla~6. ER and/or progesterone receptor(PgR) positive(≥10% of the cells by IHC)~7. HER2 negative(by IHC and/or FISH)~8. Premenopause status (estradiol in premenopausal range or with normal menstrual cycle in the past 6 months with no use of hormonal drugs)~9. Eastern Cooperative Oncology Group（ECOG）score 0-1, an estimated life expectancy of at least 12 months~10. Adequate bone marrow function: Leukocyte ≥ 3.0\*109/L; Neutrophil ≥ 1.5\*109/L; Hb ≥ 100g/L; Platelet(PLT） ≥ 80\*109/L~11. Adequate liver, renal function and coagulation function: Alanine transaminase（ALT） and/or Aspartate transaminase（AST）≤ 1.5 upper normal limit（UNL）, total bilirubin ≤upper normal limit, creatinine ≤ 110umol/L, Creatinine clearance \> 60ml/min, blood urea nitrogen（BUN） ≤ 7.1mmol/L, activated partial thromboplastin time（APTT） ≤ 1.5 upper normal limit（UNL）~12. Women with child-bearing potential must have a negative pregnancy test (urine or serum) within 7 days of drug administration and agree to use an acceptable method of birth control to avoid pregnancy for the duration of the study~13. Serological records of hepatitis B virus（HBV）and hepatitis C virus（HCV） testing.~Exclusion Criteria:~1. Stage IV breast cancer~2. Prior systemic or loco-regional treatment of breast cancer~3. Any anti-neoplastic treatment within 28 days before the beginning of study~4. Known severe hypersensitivity to any drugs in this study~5. History of malignancy within 5 years except carcinoma in situ of cervix or skin basal cell carcinoma that had received adequate treatment~6. Peripheral neuropathy ≥ 2°, according to National Cancer Institute(NCI) Common Terminology Criteria for Adverse Events(CTCAE)(Version 4.0)~7. Any cardiac or pulmonary dysfunction defined as following:~(1) ≥ 3° symptomatic congestive heart failure (CHF) according to NCI CTCAE(Version 4.0) or ≥ 2° CHF according to New York Heart Association（NYHA）~(2) Angina that needs anti-anginal drugs, advanced conduction abnormality or significant vascular disease~(3) Uncontrolled high-risk arrhythmia: atrial tachycardia that silent heart rate \>100/min, significant ventricular arrythmia or advanced atrioventricular block(2° type II atrioventricular or 3° atrioventricular block)~(4) Poorly controlled hypertension (systolic BP \> 180 mmHg or diastolic BP \> 100 mmHg)~(5) Transmural myocardial infarction in EKG~(6) Long-term oxygen therapy~8. Uncontrolled severe systemic disease(clinically significant cardiovascular disease，pulmonary disease or metabolic disease, wound healing disorder, ulcer, severe infection)~9. Pregnant or breast feeding~10. Major operation, obvious trauma within 28 days before randomization or planned major operation during the study~11. Known active hepatic disease due to hepatitis B virus, hepatitis C virus, auto-immune liver disease or sclerosing cholangitis~12. Known HIV infection~13. Any reasons investigators consider that not suitable for the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neoadjuvant endocrine therapy (Type: EXPERIMENTAL): Six months of exemestane or anastrozole plus goserelin.
- Neoadjuvant chemotherapy (Type: ACTIVE_COMPARATOR): Six cycles of docetaxel plus epirubicin and cyclophosphamide(TEC).

Based on this trial design, predict the completion outcome and termination type (if applicable).